A Pennsylvania-based biotech firm has appointed a new chief scientific and medical officer to the company’s leadership team following the acquisition of rights to an allogeneic immuno-oncology platform and a clinical-stage program.
Coeptis Therapeutics Holdings Inc. of Wexford, Pennsylvania, announced that Dr. Colleen Delaney assumes the post as a result of a recent agreement Coeptis made with Deverra Therapeutics.
Delaney, who has more than two decades of experience as an oncologist and stem cell…